{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:36:05Z","timestamp":1790465765751,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Acute myeloid leukemias (AMLs) are a group of hematologic malignancies that are heterogeneous in their molecular and immunophenotypic profiles. Identification of the immunophenotypic differences between AML blasts and normal myeloid hematopoietic precursors (myHPCs) is a prerequisite to achieving better performance in AML measurable residual disease follow-ups. In the present study, we applied high-dimensional analysis algorithms provided by the Infinicyt 2.0 and Cytobank software to evaluate the efficacy of antibody combinations of the EuroFlow AML\/myelodysplastic syndrome panel to distinguish AML blasts with recurrent genetic abnormalities (<jats:italic>n<\/jats:italic> = 39 AML samples) from normal CD45<jats:sup>low<\/jats:sup> CD117+ myHPCs (<jats:italic>n<\/jats:italic> = 23 normal bone marrow samples). Two types of scores were established to evaluate the abilities of the various methods to identify the most useful parameters\/markers for distinguishing between AML blasts and normal myHPCs, as well as to distinguish between different AML groups. The Infinicyt Compass database-guided analysis was found to be a more user-friendly tool than other analysis methods implemented in the Cytobank software. According to the developed scoring systems, the principal component analysis based algorithms resulted in better discrimination between AML blasts and myHPCs, as well as between blasts from different AML groups. The most informative markers for the discrimination between myHPCs and AML blasts were CD34, CD36, human leukocyte antigen-DR (HLA-DR), CD13, CD105, CD71, and SSC, which were highly rated by all evaluated analysis algorithms. The HLA-DR, CD34, CD13, CD64, CD33, CD117, CD71, CD36, CD11b, SSC, and FSC were found to be useful for the distinction between blasts from different AML groups associated with recurrent genetic abnormalities. This study identified both benefits and the drawbacks of integrating multiple high-dimensional algorithms to gain complementary insights into the flow-cytometry data.<\/jats:p>","DOI":"10.3389\/fcell.2021.735518","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T07:15:49Z","timestamp":1632813349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Advanced Flow Cytometry Analysis Algorithms for Optimizing the Detection of \u201cDifferent From Normal\u201d Immunophenotypes in Acute Myeloid Blasts"],"prefix":"10.3389","volume":"9","author":[{"given":"Carmen-Mariana","family":"Aanei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Veyrat-Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rigollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Stagnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Tavernier Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Campos Catafal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22659-1","article-title":"Differential expression pattern of co-inhibitory molecules on CD4+ T cells in uncomplicated versus complicated malaria.","volume":"8","author":"Abel","year":"2018","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.","volume":"31","author":"Amir el","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2018.11.014","article-title":"Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: is multicentric MRD assessment feasible?","volume":"76","author":"Brooimansa","year":"2019","journal-title":"Leuk. Res."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190468","article-title":"Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin\u2019s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma.","volume":"13","author":"Byford","year":"2018","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.4049\/jimmunol.1500633","article-title":"Algorithmic tools for mining high-dimensional cytometry data.","volume":"195","author":"Chester","year":"2015","journal-title":"J. Immunol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/leu.2010.160","article-title":"Automated pattern-guided principal component analysis vs. expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardisation of clinical immunophenotyping.","volume":"24","author":"Costa","year":"2010","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma.","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B"},{"key":"B8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.18632\/oncotarget.27439","article-title":"Immune system and bone microenvironment: rationale for targeted cancer therapies.","volume":"11","author":"Gnoni","year":"2020","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578176","article-title":"Method for the analysis of the tumor microenvironment by mass cytometry: application to chronic lymphocytic leukemia.","volume":"11","author":"Gonder","year":"2020","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/ni0706-681","article-title":"Interpreting flow cytometry data: a guide for the perplexed.","volume":"7","author":"Herzenberg","year":"2006","journal-title":"Nat. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cyto.b.20485","article-title":"Considerations for the control of background fluorescence in clinical flow cytometry.","volume":"76","author":"Hulspas","year":"2009","journal-title":"Cytometry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytometry A"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4049\/jimmunol.1701494","article-title":"Beginner\u2019s guide to analyzing and visualizing mass cytometry data.","volume":"200","author":"Kimball","year":"2018","journal-title":"J. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"10.17.1","DOI":"10.1002\/0471142956.cy1017s53","article-title":"Chapter 10- Web-based analysis and publication of fow cytometry experiments","author":"Kotecha","year":"2010","journal-title":"Current Protocols in Cytometry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68468-3","article-title":"Standardization procedure for flow cytometry data harmonization in prospective multicenter studies.","volume":"10","author":"Le Lann","year":"2020","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2017.313","article-title":"Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.","volume":"32","author":"Lhermitte","year":"2018","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/471-2105-10-145","article-title":"flowClust: a bioconductor package for automated gating of flow cytometry data.","volume":"10","author":"Lo","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/eji.201545774","article-title":"The end of gating? An introduction to automated analysis of high dimensional cytometry data.","volume":"46","author":"Mair","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/cyto.b.21219","article-title":"Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry.","volume":"92","author":"Matarraz","year":"2017","journal-title":"Cytometry B Clin. Cytom."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jid.2017.03.002","article-title":"Research techniques made simple: mass cytometry analysis tools for decrypting the complexity of biological systems.","volume":"137","author":"Matos","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4110\/in.2013.13.2.43","article-title":"Multiparameter flow cytometry: advances in high resolution analysis.","volume":"13","author":"O\u2019Donnell","year":"2013","journal-title":"Immune Netw."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112684","article-title":"Immunophenotypic dissection of normal hematopoiesis.","volume":"475","author":"Orfao","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.07.003","article-title":"From big flow cytometry datasets to smart diagnostic strategies: the EuroFlow approach.","volume":"475","author":"Pedreira","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-4939-9454-0_20","article-title":"Supervised machine learning with CITRUS for single cell biomarker discovery.","volume":"1989","author":"Polikowsky","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nbt.991","article-title":"Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE.","volume":"29","author":"Qiu","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/cyto.b.21087","article-title":"Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.","volume":"84","author":"Sandes","year":"2013","journal-title":"Cytometry B Clin. Cytom."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cyto.a.23844","article-title":"Standardization of flow cytometric immunophenotyping for hematological malignancies: the FranceFlow group experience.","volume":"95","author":"Solly","year":"2019","journal-title":"Cytometry A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardised flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B33","first-page":"124","article-title":"Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.","volume":"1","author":"Webber","year":"2008","journal-title":"Int. J. Clin. Exp. Pathol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.735518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T07:15:57Z","timestamp":1632813357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.735518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":33,"alternative-id":["10.3389\/fcell.2021.735518"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.735518","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"article-number":"735518"}}